Trial Profile
NGR015: Randomized Double-blind Phase III Study of NGR-hTNF Plus Best Investigator's Choice (BIC) Versus Placebo Plus BIC in Previously Treated Patients With Advanced Malignant Pleural Mesothelioma (MPM).
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs NGR-TNF (Primary) ; Doxorubicin; Gemcitabine; Vinorelbine
- Indications Malignant-mesothelioma
- Focus Registrational; Therapeutic Use
- Sponsors AGC Biologics
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology
- 17 May 2018 According to a MolMed media release, new clinical outcome data of NGR-hTNF in brain lymphoma will be presented at the American Society of Clinical Oncology 2018.
- 09 May 2018 Results published in the Lancet Oncology